Patent life of antiretroviral drugs approved in the US from 1987 to 2007
Rodriguez-Monguio R et al. - The effective patent life listed for the last patent of seven ARV NMEs exceeded 20 years. Shortening the drug approval process increased the effective patent life of ARVs and facilitated faster entry of new drugs into the market. ARVs had an average of 2-3 more years of effective patent life than other therapeutic classes and, therefore, a longer period without generic competition. [more...]
|
|
|
